LONDON/NEW YORK - Biotechnology company Compass Pathways plc (NASDAQ:CMPS) announced Tuesday the appointment of Justin Gover to its Board of Directors, effective immediately, as the company prepares ...

LONDON & NEW YORK, April 29, 2025--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today ...

Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved “Steve has spent the past four years working to deeply ...

Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to the Board of Directors, highlighting his experience with "Epidiolex, the ...

COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with ...

Compass Pathways is advancing clinical trials for COM360, with data from the COMM-five trial expected soon. The company plans to leverage SPRAVATO’s infrastructure for COM360’s commercialization.

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...